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Aims The purpose of this study was to evaluate the cost-effectiveness of iron repletion using intravenous (i.v.) ferric car-
boxymaltose (FCM) in chronic heart failure (CHF) patients with iron deﬁciency with or without anaemia. Cost-ef-
fectiveness was studied from the perspective of the National Health Service in the UK.
Methods
and results
A model-based cost-effectiveness analysis was used to compare iron repletion with FCM with no iron treatment.
Using data from the FAIR-HF trial and publicly available sources and publications, per patient costs and clinical effect-
iveness of FCM were estimated compared with placebo. Cost assessment was based on study drug and administration
costs, cost of CHF treatment, and hospital length of stay. The incremental cost-effectiveness ratio (ICER) of FCM use
was expressed as cost per quality-adjusted life year (QALY) gained, and sensitivity analyses were performed on the
base case. The time horizon of the analysis was 24 weeks. Mean QALYs were higher in the FCM arm (difference
0.037 QALYs; bootstrap-based 95% conﬁdence interval 0.017–0.060). The ICER of FCM compared with placebo
was E4414 per QALY gained for the FAIR-HF dosing regimen. Sensitivity analyses conﬁrmed the base case result
to be robust.
Conclusion From the UK payers’ perspective, managing iron deﬁciency in CHF patients using i.v. FCM was cost-effective in this
analysis. The base case ICER was clearly below the threshold of E22 200–E33 300/QALY gained (£20 000–£30
000) typically used by the UK National Institute for Health and Clinical Excellence and proved to be robust in sen-
sitivity analysis. Improved symptoms and better quality of life contributed to this result.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Chronic heart failure (CHF) patients are often limited in their daily
activities. Frequently reported symptoms are fatigue and dyspnoea,
but also impaired physical working capacity, exhaustion,
susceptibility to stress, and decreased mental and cognitive per-
formance.
1,2 Anaemia and iron deﬁciency are common ﬁndings in
HF patients and may partially explain these symptoms. Anaemic
HF patients are at risk of increased mortality, number of hospitali-
zations, and levels of natriuretic peptides, and reduced exercise
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3 Factors (e.g. renal dys-
function, haemodilution, and drugs) present in HF can contribute
to the development of anaemia.
3 A recent study found profound
and general bone marrow dysfunction in CHF patients, another
factor contributing to anaemia.
4 Iron plays a key role in the
uptake, transport, and storage of oxygen, which in CHF is often in-
sufﬁciently supplied to the body. Iron deﬁciency in HF patients can
exacerbate chronic diseases, and affects erythropoiesis and oxida-
tive and immune mechanisms.
3 In recent years, clinical research in-
creasingly focused on iron therapy and administration of
erythropoiesis-stimulating agents (ESAs) as treatment strategies
for anaemia and iron deﬁciency in CHF patients.
5 Intravenous
(i.v.) iron repletion with ferric carboxymaltose (FCM) has been
shown to improve symptoms and QoL in patients with CHF.
6–8
FAIR-HF (see Appendix), a randomized, double-blind, placebo-
controlled trial (n ¼ 459) studied clinical and QoL beneﬁts of
treatment with FCM, an i.v. iron preparation, in iron-deﬁcient
CHF patients with New York Heart Association (NYHA) class II
or III, a left ventricular ejection fraction of ≤ 40% (for patients in
NYHA class II) or ≤ 45% (for patients in NYHA class III), a haemo-
globin level at the screening visit of between 9.5 and 13.5 g/dL, and
iron deﬁciency.
9 Causes of HF in FAIR-HF patients were predom-
inantly ischaemic [FCM n (%) 245 (80.6); placebo 123 (79.4)].
6
Primary and secondary endpoints included NYHA functional
class change from baseline and European Quality of Life-5 Dimen-
sions (EQ-5D; EuroQol Group, Rotterdam, The Netherlands)
questionnaire-based health-related quality of life (HRQoL).
10 The
FAIR-HF trial showed signiﬁcantly better NYHA class changes
from baseline in the FCM group compared with placebo, and
FCM resulted in improved HRQoL [increased EQ-5D visual ana-
logue scale (VAS) score change from baseline].
6 This study evalu-
ated the cost-effectiveness of iron repletion using i.v. FCM in
CHF patients, from the perspective of the National Health
Service (NHS) in the UK.
Methods
We performed a model-based cost-effectiveness analysis compar-
ing a strategy of iron repletion with FCM with a standard strategy
of no iron treatment in iron-deﬁcient patients with or without
anaemia. These strategies were generally equivalent to the strat-
egies investigated in the FAIR-HF trial.
9 Cost differences between
the treatment strategies were also modelled and are reported in
the Results section. A decision-tree model was used to facilitate
sensitivity analysis. It allowed for performing deterministic as well
as probabilistic sensitivity analyses.
The population basis for the clinical model inputs consisted of
the 459 patients with NYHA functional class II and III at baseline,
which formed the intention-to-treat (ITT) population of the
FAIR-HF trial. Baseline characteristics are shown in Table 1. The
FAIR-HF trial did not include British patients but was mostly per-
formed in European countries (including Russia and Ukraine)
with a predominantly Caucasian population. Therefore, the
authors assume that clinical study results in a British population
would not differ signiﬁcantly from those of the actual trial.
In FAIR-HF, patients were randomly assigned to receive either
FCM or placebo (normal saline). During a correction phase,
patients received weekly injections until iron repletion was
achieved.
6 The total iron dose required for iron repletion was cal-
culated at baseline using the Ganzoni formula.
6 FCM was adminis-
tered as an i.v. bolus injection of 4 mL equivalent to 200 mg of iron
until repletion was achieved. Subsequently, during a maintenance
phase, an injection was given every 4 weeks. Patients were assessed
for NYHA functional class and QoL at baseline and Weeks 4, 12,
and 24. QoL was represented by health state utilities measured
with the EuroQol Group 5-Dimension Self-Report Questionnaire
(EQ-5D). The EQ-5D is an instrument designed for self-
completion by respondents. The instrument comprises two
parts: ﬁrst, respondents report their health status according to a
ﬁve-dimensional classiﬁcation (mobility, self-care, usual activities,
pain/discomfort, anxiety/depression). Each dimension is repre-
sented by a three-level ordered category item, which leads to a
total of 243 possible health ratings that are valued using the stand-
ard UK time trade-off value set. Secondly, the respondents record
their self-perceived health status using a graduated visual analogue
scale (VAS), with grades from 0 to 100. The EQ-5D is a generic
QoL instrument which has been validated and shown to be sensi-
tive, internally consistent, and reliable in the general population and
different patient groups.
11–13
In the cost-effectiveness analysis, available outcome measures
for the different strategies assessed were (i) cost; (ii) effectiveness,
expressed as the number of quality-adjusted life years (QALYs)
accrued during the study period; and (iii) the incremental cost-
effectiveness ratio (ICER), expressed as cost per QALY gained.
Costs are reported in Euros (E) and Pounds sterling (£). For the
conversion of £ to E, an exchange rate of 1.11 was used (mean
exchange rate for 2009; source: www.oanda.com). Costs and
................................................................................
Table 1 Baseline demographic and clinical
characteristics of the FAIR-HF intention-to-treat
population, according to study group
Variable Ferric
carboxymaltose
(n 5 304)
Placebo
(n 5 155)
Age, years 67.8+10.3 67.4+11.1
Female sex 159 (52.3) 85 (54.8)
NYHA class
II 53 (17.4) 29 (18.7)
III 251 (82.6) 126 (81.3)
Left ventricular ejection
fraction, %
31.9+5.5 33.0+6.1
Laboratory measurements
Haemoglobin, g/L
a 119+12.6 119.5+13.8
Serum ferritin, mg/L 52.5+54.5 60.1+66.5
Transferrin saturation,% 17.7+12.6 16.7+8.4
Data presented are the mean value+SD or number (%) of patients. Values were
calculated from the study data by the authors. In the FAIR-HF trial a 2:1
randomization was used.
9
NYHA, New York Heart Association.
aDue to missing values, the n for haemoglobin are 298 (ferric carboxymaltose) and
153 (placebo).
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study period. Where necessary, cost information was inﬂation cor-
rected using the ‘Unit Costs of Health and Social Care’ inﬂation
indices of the Personal Social Services Research Unit (PSSRU).
14
Costs borne by the patient and society as a whole were not incor-
porated, as they are not relevant from the NHS perspective.
The time horizon of the analysis was 24 weeks, corresponding
to the duration of the FAIR-HF trial. Extrapolation of the time
horizon to a longer term, e.g. lifelong time horizon, was not con-
sidered adequate as the FAIR-HF trial provides no information on
longer term survival or other long-term effects. In the FAIR-HF
trial, the rates of death, hospitalization, and serious or any
adverse events were similar in the two study groups.
6
Two approaches to cost estimation were used, as there was no
detailed medical resource use information available that would
have allowed direct assessment of direct medical costs. (i) In the
base case analysis, only CHF-related hospitalization costs were
taken into account. (ii) In a univariate sensitivity analysis, the
costs of CHF treatment were estimated using cost proportions
observed for patients in different NYHA classes.
In both approaches, UK FCM costs and UK FCM administration
costs
15,16 were additionally taken into account. Costs for adverse
events were not included because there were not any clinically
relevant differences between the FAIR-HF study arms. Table 3 pro-
vides an overview of the different approaches used in the analysis.
All data derivations from the FAIR-HF raw data were performed by
the authors and checked for consistency with the publication by
Anker et al.
6 where applicable.
Model inputs
Clinical data
The EQ-5D questionnaire (base case analysis) and VAS (sensitivity
analysis) results from FAIR-HF,
6 measured at baseline and at
Weeks 4, 12, and 24, were converted into utility values as
described above. QALYs were calculated by multiplying these util-
ities by the appropriate time periods for each individual. In order
to achieve this, any changes in utility were assumed to occur in
the middle of the periods deﬁned by the assessment time points.
Observations with missing values were imputed with the value of
the last observation (last observation carried forward; LOCF), as
was done in the FAIR-HF main clinical publication. Effectiveness
was assessed as the number of QALYs accrued during the study.
Clinical response to treatment, measured by change in NYHA
class, was also assumed to be the same as in FAIR-HF.
Medical resource use
In the base case analysis, medical resources taken into account
were drug (FCM), FCM administration, and hospitalization for
CHF (Table 2). Concerning drug usage, there was no wastage, as
FCM vials were fully administered in each case. Hospitalization
costs were determined by multiplying UK-based hospital length
of stay for CHF patients
17by the average number of hospitaliza-
tions seen in placebo patients in the FAIR-HF trial and, for patients
in the FCM group, by the proportional length of stay in the FCM
arm (average length of stay across all patients and hospitalizations
in the FCM group divided by average length of stay in the placebo
group). For patients remaining hospitalized after 24 weeks an arti-
ﬁcial discharge date (baseline plus 24 weeks) was assumed.
In the second, NYHA class-based approach to cost estimation,
CHF-related medical resource use (other than for FCM and
FCM administration) was assumed to be represented by the
typical cost of a patient falling into a given NYHA class: cost pro-
portions observed for CHF patients in different NYHA classes
published by Levin and Szucs
18,19 were multiplied by published
total costs for CHF patients
20 and patient days per NYHA class
according to data from the FAIR-HF study arms.
Unit costs
Costs for a hospital day for CHF patients were calculated using
2008–2009 NHS reference costs
21 (Table 2). For FCM, the UK
purchasing price (PP) was used in the base case analysis.
22 Ambu-
latory administration costs were calculated using information on
wages from the PSSRU data on unit costs for medical services.
15
Costs of materials were taken into account according to informa-
tion from the Falkirk & District Royal Inﬁrmary.
16
Sensitivity analysis
In order to assess the impact of statistical uncertainty around key
model inputs, we performed a series of univariate and probabilistic
sensitivity analyses.
Univariate sensitivity analyses
In univariate sensitivity analysis, we varied (i) the mean duration of
hospitalizations for CHF in the UK and (ii) the cost of a hospital
day by +30%; and (iii) drug costs by +10% as no conﬁdence
intervals were available for these parameters. We further varied
(iv) QALY difference; (v) proportional reduction of hospitalization
days; and (vi) frequency of hospitalization in the placebo group on
the basis of their conﬁdence intervals. Further variations were:
(vii) calculation of results considering only cases with complete
data on utilities; (viii) calculation of costs via the NYHA class ap-
proach; and (ix) calculation of utilities using EQ-5D VAS scale
scores.
Probabilistic sensitivity analyses
Probabilistic sensitivity analysis (second-order Monte Carlo simula-
tion; PSA) was based on distributions corresponding to the ranges
of variation used in the univariate sensitivity analyses assessing
the impact of parameter uncertainty (Table 2). PSA was based on
10 000 sets of randomly drawn input parameters.
Technical implementation
The model was implemented and all Monte Carlo analyses were
performed using TreeAge Pro 2011 Suite (TreeAge Software
Inc., Williamstown, MA, USA). Further analyses were performed
using Stata/IC 11 (StataCorp LP, College Station, TX, USA).
Results
Characteristics of the study patients
The clinical characteristics of the FAIR-HF ITT population are pre-
sented in Table 1. At baseline, there were 53 patients (17.4%) in
NYHA functional class II and 251 (82.6%) in class III in the
F.S. Gutzwiller et al. 784treatment group, and 29 patients (18.7%) in class II and 126
(81.3%) in class III in the placebo group.
Cost-effectiveness of intravenous iron
therapy
In the base case analysis, mean QALYs were higher in the FCM
arm (placebo, 0.298; FCM, 0.336); the difference was 0.037
QALYs [bootstrap-based 95% conﬁdence interval (CI) 0.017–
0.060] (cost and cost-effectiveness results are shown in
Table 3). The ICER of FCM compared with placebo was E4414
(£3977) per QALY gained for the FAIR-HF dosing regimen.
The FCM group yielded total costs of E852 (£768) and the
placebo group of E687 (£619) over the study period. There
were costs of E393 (£354) for the drug and E211 (£190) for ad-
ministration compared with no costs on the placebo side. On the
other hand, treatment with FCM saved E438 (£395) of costs for
hospital treatment [FCM, E249 (£224); placebo, E687 (£619)],
resulting in a net cost of the FCM strategy of E165 (£149)
over 24 weeks.
Sensitivity analysis
Univariate sensitivity analysis was carried out to characterize the
robustness of the base case results. Results ranged from domin-
ance (i.e. being both cost saving and more effective) of the i.v.
iron strategy [E1045 (£941) saved; effectiveness 0.037 QALYs]
to E13 855 (£12 482) per QALY gained. Frequency and duration
of hospitalization, QALY difference, and cost of a hospital day were
the most inﬂuential parameters. Univariate sensitivity analysis
results are presented in Table 3 and summarized in a Tornado
diagram (Figure 1).
Analysis of mean days spent in each NYHA class, for FCM
(placebo), resulted in 6.5 days (1) for NYHA class I, 58 days
(40) for NYHA class II, 100 days (119) for NYHA class III, and
,1 day (3) for NYHA class IV. The approach of assessing CHF
treatment costs based on the time spent in each NYHA class
resulted in costs of E1907 (£1718) for FCM and E1361 (£1226)
for placebo, with a cost difference of E546 (£492) and a resulting
ICER of E14 582 (£13 137), if the proportions according to
Levin
18 were used. If the distribution according to Szucs
19 was
used, costs were E1415 (£1275) for FCM and E887 (£799) for
placebo, with a cost difference of E528 (£476) and a resulting
...............................................................................................................................................................................
Table 2 Model input parameters, ranges of variation, and distribution type, in sensitivity analyses
Resource use Unit Value Range of variation
in deterministic
sensitivity analysis
Distribution type in
probabilistic sensitivity
analysis
Mean dose
a of FCM received per
patient
6
mg 1851.33 1802.12–1900.54 Normal
Mean number of push injections
(200 mg)
a in FCM arm
6
– 9.46 9.21–9.72 Normal
UK hospital length of stay for
CHF
17
Days 11.8 8.26–15.34 Triangular
Relative length of stay
b in
FAIR-HF in FCM arm relative
to placebo arm
6
– 0.36 0.16–0.88
c Lognormal
Length of stay
d per
hospitalization
6
Days No iron: 2.95 FCM: 1.07 – –
Frequency
d of hospitalizations
6 – No iron: 0.17 FCM: 0.08 – –
Unit cost
FCM costs
Costs FCM (PP; per 100 mg)
22 E (£) 21.20 (19.10) 18.03
e (16.24) –
Administration costs
Push injection (wages and
material)
15,16
E (£) 22.36 (20.14) 15.64–29.06 (14.09–26.18) Triangular
Costs per hospital day for CHF
21 E (£) 347.27 (312.86) 243.09–452.57 (219.00–407.72) Triangular
Other variables used in sensitivity analysis
QALY difference between arms
f – 0.037 0.02–0.06
c Normal
Data presented are rounded values.
E, euros; £, pounds sterling; CHF, chronic heart failure; FCM, ferric carboxymaltose; PP, purchasing price; QALY, quality-adjusted life year.
aDue to missing data, seven patients were excluded from summary statistics.
bCumulative over the study period.
cBootstrap-based conﬁdence intervals.
dRepresented in the model by the combined parameter ‘relative length of stay in FAIR-HF’.
eUsed in scenario analysis.
fQALY difference as a clinical study endpoint is shown here because it was used for probabilistic sensitivity analysis.
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Table 3 Overview of different approaches to analysis and results
Calculation Cost difference, E (£)
a QALY difference ICER, E (£)
Base case analysis
Cost via hospital days, EQ-5D questionnaire derived scores, all cases (LOCF) 165 (149) 0.037 4414 (3977)
Univariate sensitivity analysis
Topic Variable Variation Cost difference, E (£)
a QALY difference ICER, E (£)
Costs Cost of a hospital day varied by –30% 297 (268) 0.037 7919 (7134)
+30% 34 (31) 905 (815)
Cost of an ambulatory injection 230% 102 (92) 2722 (2452)
+30% 229 (206) 6108 (5503)
Calculation of costs via NYHA class approach According to
18 528 (476) 14 096 (12 699)
According to
18 546 (492) 14 582 (13 137)
Drug costs varied by –10% 127 (114) 3368 (3034)
+10% 204 (184) 5462 (4921)
Resources Duration of hospitalization for CHF in the UK –30% 297 (268) 7925 (7140)
+30% 34 (31) 905 (815)
Proportional reduction of hospitalization days Lower margin of CI 23 (21) 616 (555)
Upper margin of CI 519 (468) 13 855 (12 482)
Frequency of hospitalization in placebo group Lower margin of CI 316 (285) 8443 (7606)
Upper margin of CI –39 (–35) FCM dominant
Mean dose of FCM received per patient Lower margin of CI 155 (140) 4136 (3726)
Upper margin of CI 175 (158) 4693 (4228)
Mean number of push injections in FCM arm Lower margin of CI 160 (144) 4264 (3841)
upper margin of CI 171 (154) 4565 (4113)
Utilities QALY difference Lower margin of CI 165 (149) 0.017 9673 (8714)
Upper margin of CI 0.060 2738 (2467)
QALYs Complete records only 0.039 4208 (3791)
Computation of utilities VAS scale-derived scores 0.023 7201 (6487)
Data shown are cost difference (E/£), QALY difference, and resulting ICER (E/£) of base case analysis and sensitivity analyses.
E, euros; £, pounds sterling; CHF, chronic heart failure; CI, conﬁdence interval; FCM, ferric carboxymaltose; ICER, incremental cost-effectiveness ratio; LOCF, last observation carried forward; NYHA, New York Heart Association; QALY,
quality-adjusted life year; VAS, visual analogue scale.
aPositive numbers indicate that FCM is more expensive than placebo.
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6ICER of E14 096 (£12 699). None of the parameters tested
resulted in an ICER less favourable than E22 200–E33 300/
QALY gained (£20 000–£30 000), the threshold usually regarded
as acceptable by the UK National Institute for Health and Clinical
Excellence (NICE).
23
The PSA results showed mean costs of E877 (£790) for FCM
and E686 (£618) for placebo [range: FCM, E608–E2050
(£548–£1847); placebo, E369–E1112 (£332–£1002)] and a
mean effect of 0.038 QALYs (range –0.006 to 0.085). A total of
9866 scenarios (98.66%) were better than E22 200; 9968 scen-
arios (99.68%) were better than E33 300. A cost-effectiveness
scatterplot and cost-effectiveness acceptability curve are shown
in Figures 2 and 3, respectively. Generally, sensitivity analyses
showed the results to be robust.
Discussion
As the cost burden of CHF reaches up to 1–2% of healthcare
budgets, cost-effective treatments to improve symptoms and
QoL are needed.
24 The cost-effectiveness of iron repletion using
FCM, compared with no iron treatment, in CHF patients with
iron deﬁciency derived from our trial-based analysis (E4414/
QALY gained in the base case) was clearly below the cost-
effectiveness threshold typically regarded as acceptable by NICE,
of E22 200–E33 300/QALY gained.
23 Mean QALYs were higher
in the FCM arm, and improved symptoms and better quality of
life contributed to economic beneﬁts seen with FCM. Sensitivity
analyses showed ranges of QALY differences (ICERs) from 0.017
to 0.060 (FCM dominant: E13 855) for the univariate and
QALYs of –0.006 to 0.085 for the probabilistic analysis.
To the authors‘ knowledge FAIR-HF is the ﬁrst study that com-
pared FCM with placebo in a population of CHF patients with iron
deﬁciency. Clinical implications of FCM use compared with other
i.v. and oral iron compounds have been studied in various indica-
tions. Cost-effectiveness analyses of FCM use are scarce across
indications, and none is available for CHF patients.
The use of ESAs in CHF patients is still under debate, and
further research is needed in this regard.
5 If ESA treatment was
established as a therapeutic option, combination treatment with
i.v. iron might have fewer cost implications in the long run
than ESA treatment alone, as required ESA doses might be
reduced.
25–29
One important limitation of the present analysis is the lack of ex-
haustive medical resource use information; data on some uses of
medical resources such as co-medications, devices (e.g. pace-
makers), and ambulatory treatments could not be accounted for
in the analysis, as they were not recorded in the FAIR-HF trial.
As there is no indication of an increased use of unmeasured re-
source items in patients treated with i.v. iron vs. patients with no
iron treatment, the authors do not expect that other resource
items, had they been included in the analysis, would diminish the
cost difference between FCM and placebo. The strategy to
assess treatment costs via hospital days is likely to produce conser-
vative results, because other potential resource savings, relating,
Figure 1 Tornado diagram of deterministic sensitivity analyses addressing the impact of parameter uncertainty. E, euros; CHF, chronic heart
failure; ICER, incremental cost-effectiveness ratio; QALY, quality-adjusted life year.
Ferric carboxymaltose in patients with iron deﬁciency and CHF 787Figure 2 Cost-effectiveness scatterplot of 10 000 bootstrap replicates for incremental cost and incremental effectiveness. The circle is
depicting 95% of observations. For each simulation run (represented as a dot), parameters were simultaneously and randomly sampled
from the probability, cost, and outcome distributions for each strategy, to account for uncertainty in the base case parameter estimates. All
simulation results fell in two quadrants of the cost-effectiveness plain: quadrant I (upper right), where the FCM strategy was both more
costly and more effective than placebo, or quadrant II (lower right), where the FCM strategy was less costly and more effective. E, euros;
FCM, ferric carboxymaltose; QALYs, quality-adjusted life years.
Figure 3 For different willingness-to-pay values, the cost-effectiveness acceptability curve (CEAC) shows the probability that the ferric car-
boxymaltose (FCM) strategy (blue line) is cost-effective compared with placebo. The willingness-to-pay can be interpreted as the maximum
amount one would be willing to pay for a gain of one quality-adjusted year of life. E, euros; QALY, quality-adjusted life years.
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tion. In an alternative approach to cost assessment, treatment
costs for CHF patients were estimated using the time spent in
each NYHA class, and resulted in ICERs that are almost three-fold
compared with the approach of using hospital days to estimate
costs. Although the level of healthcare expenditure has been
shown to be associated with NYHA class, this approach apparently
cannot appropriately reﬂect changes in hospitalization rate and
duration, as observed in FAIR-HF. Moreover, clinical treatment
regimens most probably will not immediately follow and be
adapted to changes in NYHA class (particularly improvements),
preventing a rapid translation into cost changes. While it is of inter-
est to study the distribution of CHF costs across NYHA classes,
reverse use of such information to predict costs in other situations
does not appear to be a suitable option. The study by Szucs et al.
19
is based on a random sample of CHF outpatients in Switzerland,
whereas the study by Levin et al. is based on the CHARM-trial,
30
which contains data from CHF patients in 26 countries; both
studies date back to 1999.
Some model inputs used in this analysis were subject to substan-
tial uncertainty. It may, for example, be questionable whether
NHS-reported Healthcare Resource Group (HRG) costs really
reﬂect actual hospitalization costs. In the NYHA-based analysis,
the most uncertain variable represented UK yearly costs for
CHF treatment.
When discussing the generalizability of the presented results, it
has to be noted that in routine clinical practice, fewer FCM admin-
istrations may be required, as FCM allows injections or infusions of
up to 1000 mg in 15 min, which may lead to improved ICERs. The
extent to which this dosing regime may be achieved remains uncer-
tain. Our analysis was based on average hospitalization rates and
lengths of stay. In routine practice, wide value ranges may occur
and resource use may be structured differently, which could lead
to an under- or overestimation of costs.
The effect of FCM was seen in a closely followed patient group
with high NYHA classes(   20% NYHA II and 80% NYHA III)
and may be different in other collectives. Compared with a UK
routine practice population, the FAIR-HF population was older,
consisted of more females, and had lower diastolic and systolic
blood pressure and higher co-morbidity.
31 The impact of such
differences is not currently predictable. The results of FAIR-HF
stem from mostly pan-European study sites. There were no
sites in the UK, but given the large European contribution one
can assume that transferability of results to the UK is not sub-
stantially affected by geographical clinical variation. An analysis
of anaemic vs. non-anaemic subgroups was not performed, as
sample sizes would have been inadequate to perform a reliable
analysis.
Study data cover a period of 24 weeks of treatment. Extrapola-
tion of the time horizon to a longer term, e.g. a lifelong time
horizon, was not considered adequate as the FAIR-HF trial pro-
vides no information on long-term survival or other long-term
effects. The cost-effectiveness of longer term iron treatment
remains unknown.
Given that the trial only collected very limited resource use data,
the results do have an approximate character to some extent. In
order to gain more in-depth knowledge about use of FCM in
CHF patients, e.g. whether treatment and cost effects are sustained
over a longer period, trials covering longer time periods and gath-
ering further resource use should be the focus of further research.
In conclusion, it can be noted that over the study period, treatment
with FCM in iron-deﬁcient CHF patients with or without anaemia
improves symptoms and is likely to be cost-effective in routine clin-
ical practice, from the perspective of the UK NHS.
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